Press release
Endometriosis Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight
Endometriosis Pipeline
Request a sample and discover the recent advances in Endometriosis Drugs @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Endometriosis Pipeline Report
• In August 2026, Medicus Pharma received UAE regulatory clearance to initiate its Phase IIa PRECISION-E2 trial evaluating teverelix in women with moderate-to-severe endometriosis using a genomics-guided precision medicine approach.
• In August 2026, Sunshine Biopharma announced Canadian approval for its 2 mg generic dienogest tablets for pelvic pain associated with endometriosis, with commercial availability expected by the end of 2026.
• DelveInsight's Endometriosis Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline Endometriosis drugs.
• The leading Endometriosis Companies such as Hope Medicine (Nanjing) Co., Ltd, TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp and others.
• Promising Endometriosis Therapies such as Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219 and others.
Find out more about Endometriosis Drugs @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Endometriosis Overview
Endometriosis is defined as the presence of endometrial glands and stroma like lesions outside of the uterus. The lesions can be peritoneal lesions, superficial implants or cysts, or deep infiltrating disease. While there is no definitive etiology of endometriosis, there are several hypotheses regarding how endometriotic lesions develop. One possible mechanism is retrograde, a feature of the menstrual cycle in women and non-human primates, which is an outflow of the endometrial lining through the patent fallopian tubes into the pelvic space. This retrograde flow, along with potential hematogenous or lymphatic circulation, may result in the seeding of endometrial tissue in ectopic sites.
Endometriosis Emerging Drugs
• HMI-115: Hope Medicine (Nanjing) Co., Ltd
HMI-115 is a first-in-class monoclonal antibody drug targeting the prolactin receptor (PRLR), that Hope Medicine owns the global rights. The product candidate is being developed for multiple indications globally. Potential indications for the antibody include Endometriosis (EM), Androgenic Alopecia (AGA), and other chronic diseases. This antibody has shown excellent characteristics in animal models including non-human primate (NHP) models and human safety. Currently the drug is in Phase III stage of its development for the treatment of Endometriosis.
• Merigolix: TiumBio
Merigolix (TU2670) is an oral GnRH antagonist that can bind to pituitary receptors to suppress estradiol hormone. The existing treatment GnRH agonists, lowers patient comfort levels as it's in an injection form and inhibits sex hormones to the level of menopause, resulting in serious side effects such as bone loss. TU2670 is an oral GnRH antagonist that only suppresses hormone levels to the level of efficacy, improving both side effects and ease of administration by oral. In addition, being a sex hormone control mechanism, it allows for indication expansion to precocious puberty, test-tube baby, infertility treatment, etc. The drug is currently being evaluated under Phase II clinical trial for the treatment of endometriosis.
• Nibrozetone (RRx-001): EpicentRx
Nibrozetone, also known as RRx-001, has a unique mechanism of action that involves both anti-inflammatory and antioxidant properties. It has a dual mechanism of action, fragmenting to release metabolites such as nitric oxide (NO) and other nitrogen-centered free radicals in hypoxic environments, targeting diseases like cancer. In non-hypoxic environments, RRx-001 has anti-toxicity activity through direct inhibition of the NLRP3 inflammasome and upregulation of the master antioxidant transcription factor, Nrf2. Additionally, it inhibits the CD47 antigen, involved in immune cell function and tumor progression. Currently, the drug is in the Phase I stage of its development for the treatment of endometriosis.
The Endometriosis Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.
Learn more about Endometriosis Drugs opportunities in our groundbreaking Endometriosis research and development projects @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Endometriosis Companies
Hope Medicine (Nanjing) Co., Ltd, TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp and others
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Stay informed about how we're transforming the future of Respiratory Disease @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Scope of the Endometriosis Pipeline Report
• Coverage- Global
• Endometriosis Companies- Hope Medicine (Nanjing) Co., Ltd, TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp and others.
• Endometriosiss Therapies- Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219 and others.
• Endometriosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Endometriosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dive deep into rich insights for new Endometriosis Treatments, visit @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Table of Contents
1. Introduction
2. Executive Summary
3. Endometriosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometriosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Estelle: Gedeon Ritcher
9. Mid Stage Products (Phase II)
10. GenSci048: Changchun GeneScience Pharmaceutical Co., Ltd.
11. Early Stage Products (Phase I)
12. Preclinical and Discovery Stage Products
13. MP137P: NETRIS Pharma
14. Inactive Products
15. Endometriosis Key Companies
16. Endometriosis Key Products
17. Endometriosis- Unmet Needs
18. Endometriosis- Market Drivers and Barriers
19. Endometriosis- Future Perspectives and Conclusion
20. Endometriosis Analyst Views
21. Endometriosis Key Companies
22. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight here
News-ID: 4611798 • Views: …
More Releases from DelveInsight Business Research LLP
Lupus Nephritis Pipeline Accelerates as 35+ Pharma Companies Rigorously Develop …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 42+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Sickle Cell Disease Clinical Trial Pipeline Analysis: 55+ Key Companies Shaping …
DelveInsight's Sickle Cell Disease Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Sickle Cell Disease therapies in various stages of clinical development. The report provides insights into 55+ companies and 60+ drugs in the Sickle Cell Disease competitive landscape, covering therapeutic assessments by product type, stage, route of administration, and molecule type, as well as inactive pipeline products.
Key takeaways from the Sickle Cell Disease Clinical…
Sjogren's Syndrome Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping t …
DelveInsight's Sjogren's Syndrome Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Sjogren's Syndrome therapies in various stages of clinical development. The report provides insights into 20+ companies and 22+ pipeline drugs in the Sjogren's Syndrome pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.
Key takeaways from the Sjogren's Syndrome Clinical Trial Landscape Report
• DelveInsight's Sjogren's Syndrome pipeline report depicts a robust…
Graft Versus Host Disease Pipeline Expands as 45+ Companies Driving Innovation i …
DelveInsight's, "Graft versus host disease Pipeline Insight 2026" report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Graft versus Host Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights…
More Releases for Endometriosis
Endometriosis Treatment Market at $1.55B, 7.7% CAGR
Why Is the Global Endometriosis Treatment Market Expanding So Quickly?
The endometriosis treatment market has grown rapidly in recent years, primarily due to increased awareness, better diagnostic technologies, rising cases of reproductive health disorders, and significant investment in research and drug development. With the market valued at USD 1.55 billion in 2024 and expected to reach USD 3.25 billion by 2034, the global demand for effective treatments continues to accelerate.
Endometriosis affects…
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction
Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern.
Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays…
Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market: A Ke …
The Endometriosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Endometriosis Market Size and Its Estimated Growth Rate?
In recent years, there has been a swift expansion in the market size of endometriosis. This market is projected to increase from $1.4 billion…
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
